Altimmune to Announce First Quarter 2020 Financial Results on May 14
May 08, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first...
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
March 30, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the...
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update
March 27, 2020 07:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 27, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31,...
Altimmune to Announce Year End 2019 Financial Results on March 27
March 25, 2020 16:30 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year...
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
February 28, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal...
Altimmune to Present at the Cowen 40th Annual Health Care Conference
February 19, 2020 16:30 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg, Ph.D., President and Chief...
Altimmune to Present at Upcoming Investor and Scientific Conferences
February 04, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following...
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
January 23, 2020 07:00 ET
|
Altimmune, Inc.
Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md., Jan. 23, 2020 ...
Altimmune to Present at the 2020 NASH-TAG Conference
January 07, 2020 08:43 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference...
Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
November 21, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on...